Neuphoria Therapeutics (NEUP) Stock Overview

A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. More details

NEUP fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 79.8% below our estimate of its fair value

Earnings are forecast to grow 28.9% per year

Became profitable this year

Risk Analysis

High level of non-cash earnings

Does not have a meaningful market cap ($13M)

NEUP Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Neuphoria Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Neuphoria Therapeutics
Historical stock prices
Current Share Price	US$7.20
52 Week High	US$12.55
52 Week Low	US$2.90
Beta	0
1 Month Change	4.80%
3 Month Change	50.47%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	8.60%

Recent updates

Shareholder Returns

	NEUP	US Biotechs	US Market
7D	2.6%	2.1%	0.4%
1Y	n/a	-8.4%	12.6%

Return vs Industry: Insufficient data to determine how NEUP performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how NEUP performed against the US Market.

Price Volatility

Is NEUP's price volatile compared to industry and market?
NEUP volatility
NEUP Average Weekly Movement	9.0%
Biotechs Industry Average Movement	11.6%
Market Average Movement	7.1%
10% most volatile stocks in US Market	17.3%
10% least volatile stocks in US Market	3.7%

Stable Share Price: NEUP has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: NEUP's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1996	16	Spyros Papapetropoulos	www.neuphoriatx.com

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Neuphoria Therapeutics Inc. Fundamentals Summary

How do Neuphoria Therapeutics's earnings and revenue compare to its market cap?
NEUP fundamental statistics
Market cap	US$13.46m
Earnings (TTM)	US$5.83m
Revenue (TTM)	US$15.66m

2.3x

P/E Ratio

0.9x

P/S Ratio

Is NEUP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NEUP income statement (TTM)
Revenue	US$15.66m
Cost of Revenue	-US$1.07m
Gross Profit	US$16.73m
Other Expenses	US$10.90m
Earnings	US$5.83m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	3.10
Gross Margin	106.82%
Net Profit Margin	37.20%
Debt/Equity Ratio	0.1%

How did NEUP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/07/08 09:51
End of Day Share Price	2025/07/08 00:00
Earnings	2025/03/31
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neuphoria Therapeutics Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Tanushree Jain	Bell Potter
Esther Lannie Hong	Berenberg
Katherine Genis	Edison Investment Research